Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Cost of Revenue: 2023-2024

Historic Cost of Revenue for Iovance Biotherapeutics (IOVA) over the last 2 years, with Dec 2024 value amounting to $124.0 million.

  • Iovance Biotherapeutics' Cost of Revenue rose 22.08% to $38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $213.4 million, marking a year-over-year increase of 186.42%. This contributed to the annual value of $124.0 million for FY2024, which is 1052.91% up from last year.
  • According to the latest figures from FY2024, Iovance Biotherapeutics' Cost of Revenue is $124.0 million, which was up 1,052.91% from $10.8 million recorded in FY2023.
  • Iovance Biotherapeutics' 5-year Cost of Revenue high stood at $124.0 million for FY2024, and its period low was $10.8 million during FY2023.
  • Moreover, its 2-year median value for Cost of Revenue was $67.4 million (2023), whereas its average is $67.4 million.
  • Data for Iovance Biotherapeutics' Cost of Revenue shows a peak YoY skyrocketed of 1,052.91% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Cost of Revenue (Yearly) stood at $10.8 million in 2023, then surged by 1,052.91% to $124.0 million in 2024.